MedTrace Logo

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

NCT05803395 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 954

Last updated 2023-11-28

No results posted yet for this study

Summary

This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients who received first COVID-19 prophylaxis dose between March 2022 and October 2022.

Conditions

Sponsors & Collaborators

  • Fondazione Italiana Linfomi

    collaborator UNKNOWN

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Gian Matteo Rigolin · Ematologia - Azienda Ospedaliero Universitaria S.Anna di Ferrara

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-12
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05803395 on ClinicalTrials.gov